Strategies to guide the successful implementation of deprescribing in community practice: Lessons learned from the front line.

Justin P Turner, Kelda Newport, Aisling M McEvoy, Tara Smith, Cara Tannenbaum, Deborah V Kelly
Author Information
  1. Justin P Turner: Centre for Medicines Use and Safety, Memorial University of Newfoundland, Newfoundland and Labrador. ORCID
  2. Kelda Newport: Laval Université, Québec; and the School of Pharmacy, Memorial University of Newfoundland, Newfoundland and Labrador. ORCID
  3. Aisling M McEvoy: Centre for Medicines Use and Safety, Memorial University of Newfoundland, Newfoundland and Labrador. ORCID
  4. Tara Smith: Laval Université, Québec; and the School of Pharmacy, Memorial University of Newfoundland, Newfoundland and Labrador.
  5. Cara Tannenbaum: Faculty of Pharmacy and Pharmaceutical Sciences, Monash University, Victoria, Australia; the Faculty of Pharmacy and Medicine, Memorial University of Newfoundland, Newfoundland and Labrador.
  6. Deborah V Kelly: Laval Université, Québec; and the School of Pharmacy, Memorial University of Newfoundland, Newfoundland and Labrador. ORCID

Abstract

Background: Sustainable implementation of new professional services into clinical practice can be difficult. In 2019, a population-wide initiative called SaferMedsNL was implemented across the province of Newfoundland and Labrador (NL), to promote appropriate medication use. Two evidence-based interventions were adapted to the context of NL to promote deprescribing of proton pump inhibitors and sedatives. The objective of this study was to identify and prioritize which actions supported the implementation of deprescribing in community practice for pharmacists, physicians and nurse practitioners across the province.
Methods: Community pharmacists, physicians and nurse practitioners were invited to participate in virtual focus groups. Nominal Group Technique was used to elicit responses to the question: "What actions support the implementation of deprescribing into the daily workflow of your practice?" Participants prioritized actions within each group while thematic analysis permitted comparison across groups.
Results: Five focus groups were held in fall 2020 involving pharmacists ( = 11), physicians ( = 7) and nurse practitioners ( = 4). Participants worked in rural ( = 10) and urban ( = 12) settings. The different groups agreed on what the top 5 actions were, with the top 5 receiving 68% of the scores: (1) providing patient education, (2) allocating time and resources, (3) building interprofessional collaboration and communication, (4) fostering patient relationships and (5) aligning with public awareness strategies.
Conclusion: Pharmacists, physicians and nurse practitioners identified similar actions that supported implementing evidence-based deprescribing into routine clinical practice. Sharing these strategies may help others embed deprescribing into daily practice and assist the uptake of medication appropriateness initiatives by front-line providers. 2024;157:xx-xx.

References

  1. Can Pharm J (Ott). 2019 Nov 09;153(1):37-45 [PMID: 32002101]
  2. Can Fam Physician. 2017 May;63(5):354-364 [PMID: 28500192]
  3. J Palliat Med. 2019 Mar;22(3):335-336 [PMID: 30794498]
  4. Can Pharm J (Ott). 2018 Feb 08;151(2):133-141 [PMID: 29531631]
  5. Res Social Adm Pharm. 2020 Dec;16(12):1792-1797 [PMID: 32249103]
  6. Lancet Infect Dis. 2010 Jan;10(1):17-31 [PMID: 20129146]
  7. Can J Aging. 2017 Mar;36(1):97-107 [PMID: 28091333]
  8. Health Sci Rep. 2018 May 10;1(7):e45 [PMID: 30623083]
  9. Res Social Adm Pharm. 2021 Jul;17(7):1229-1241 [PMID: 32978088]
  10. BMJ Open. 2016 Mar 10;6(3):e009781 [PMID: 26966056]
  11. Arch Intern Med. 2010 Apr 26;170(8):693-8 [PMID: 20421554]
  12. Healthc Policy. 2019 May;14(4):39-51 [PMID: 31322113]
  13. JAMA Netw Open. 2021 Apr 1;4(4):e212633 [PMID: 33818621]
  14. Int J Gen Med. 2021 Jul 24;14:3793-3807 [PMID: 34335046]
  15. Aust J Gen Pract. 2022 Nov;51(11):845-848 [PMID: 36310001]
  16. Res Social Adm Pharm. 2020 Dec;16(12):1746-1753 [PMID: 32094042]
  17. Int J Clin Pharm. 2022 Feb;44(1):201-213 [PMID: 34642869]
  18. Basic Clin Pharmacol Toxicol. 2015 Jun;116(6):499-502 [PMID: 25382355]
  19. Pharmacy (Basel). 2018 Apr 16;6(2): [PMID: 29659488]
  20. Perm J. 2017 Apr 20;22:17-157 [PMID: 29702055]
  21. Ther Adv Drug Saf. 2018 Oct 20;9(12):687-698 [PMID: 30546863]
  22. Public Health Res Pract. 2016 Jan 28;26(1):e2611604 [PMID: 26863167]
  23. J Gerontol A Biol Sci Med Sci. 2021 May 22;76(6):1061-1067 [PMID: 32761069]
  24. Psychiatr Serv. 2008 Oct;59(10):1191-7 [PMID: 18832506]
  25. Int J Drug Policy. 2017 Jan;39:138-139 [PMID: 27856134]
  26. BMJ Open. 2014 Dec 08;4(12):e006544 [PMID: 25488097]
  27. JAMA. 2018 Nov 13;320(18):1889-1898 [PMID: 30422193]
  28. Int J Clin Pract. 2016 Mar;70(3):261-76 [PMID: 26918508]
  29. Res Social Adm Pharm. 2022 Mar;18(3):2547-2549 [PMID: 33867278]
  30. Trials. 2019 Jul 9;20(1):412 [PMID: 31288859]
  31. J Am Geriatr Soc. 2019 Apr;67(4):674-694 [PMID: 30693946]
  32. Res Social Adm Pharm. 2014 Mar-Apr;10(2):438-47 [PMID: 23880428]
  33. J Am Geriatr Soc. 2017 Dec;65(12):2691-2696 [PMID: 28913911]
  34. J Am Geriatr Soc. 2020 May;68(5):1090-1097 [PMID: 32105355]
  35. Res Social Adm Pharm. 2020 Apr;16(4):599-604 [PMID: 31303479]
  36. J Clin Pharm Ther. 2005 Oct;30(5):425-32 [PMID: 16164487]
  37. Ther Adv Drug Saf. 2018 Jul 12;9(9):559-573 [PMID: 30181862]
  38. Ann Pharmacother. 2016 Aug;50(8):625-36 [PMID: 27257284]
  39. Br J Clin Pharmacol. 2015 Dec;80(6):1254-68 [PMID: 27006985]
  40. Syst Rev. 2018 May 5;7(1):72 [PMID: 29729669]
  41. Int J Clin Pharm. 2022 Dec;44(6):1370-1379 [PMID: 36201111]
  42. BMC Fam Pract. 2020 Sep 4;21(1):183 [PMID: 32887551]
  43. Int J Qual Health Care. 2007 Dec;19(6):349-57 [PMID: 17872937]
  44. Implement Sci Commun. 2021 Jan 7;2(1):4 [PMID: 33413692]
  45. BJGP Open. 2020 Aug 25;4(3): [PMID: 32723784]
  46. Health Policy. 2021 Sep;125(9):1121-1130 [PMID: 34176672]
  47. Can Fam Physician. 2018 May;64(5):339-351 [PMID: 29760253]
  48. Ann Pharmacother. 2022 Apr;56(4):463-474 [PMID: 34301151]
  49. Int J Drug Policy. 2016 Oct;36:104-11 [PMID: 27453147]
  50. Ther Adv Drug Saf. 2018 Sep 12;9(11):653-665 [PMID: 30479740]
  51. PLoS One. 2016 Apr 19;11(4):e0151066 [PMID: 27093289]
  52. Intern Med J. 2021 Sep;51(9):1473-1478 [PMID: 33465266]
  53. J Gerontol B Psychol Sci Soc Sci. 2018 Sep 20;73(7):e98-e107 [PMID: 29190369]
  54. Aust N Z J Psychiatry. 2020 Nov;54(11):1139-1140 [PMID: 33147985]
  55. J Clin Pharm Ther. 2018 Aug;43(4):550-555 [PMID: 29682764]

Word Cloud

Created with Highcharts 10.0.0deprescribingactions=implementationpracticephysiciansnursepractitionersgroupsacrosspharmacists5clinicalprovinceNLpromotemedicationevidence-basedsupportedcommunityfocusdailyParticipants4toppatientstrategiesBackground:Sustainablenewprofessionalservicescandifficult2019population-wideinitiativecalledSaferMedsNLimplementedNewfoundlandLabradorappropriateuseTwointerventionsadaptedcontextprotonpumpinhibitorssedativesobjectivestudyidentifyprioritizeMethods:CommunityinvitedparticipatevirtualNominalGroupTechniqueusedelicitresponsesquestion:"Whatsupportworkflowpractice?"prioritizedwithingroupthematicanalysispermittedcomparisonResults:Fiveheldfall2020involving117workedrural10urban12settingsdifferentagreedreceiving68%scores:1providingeducation2allocatingtimeresources3buildinginterprofessionalcollaborationcommunicationfosteringrelationshipsaligningpublicawarenessConclusion:PharmacistsidentifiedsimilarimplementingroutineSharingmayhelpothersembedassistuptakeappropriatenessinitiativesfront-lineproviders2024157:xx-xxStrategiesguidesuccessfulpractice:Lessonslearnedfrontline

Similar Articles

Cited By